Redeye return with a research update following BioArctic's Q3 report and latest newsflow.
Q3 visade intäktstapp och ett justerat rörelseresultat på 4 Mkr, men totalt stora förluster efter en...
* Q3 adj. EBITDA 11% below FactSet consensus * Raises operating cash flow guidance * Restatements yi...
Lipum and Flerie have agreed to merge in a transaction that will see Lipum absorbed into Flerie in e...
Redeye comments on Fable Media Group taking the anticipated step toward a higher dividend, further f...
Redeye comments on Friday’s press release from Enviro, stating that the timeline for the Uddevalla p...
Redeye comments on Friday’s press release from Waystream, stating it has signed a strategic partners...
Kentima visar stark tillväxt med en omsättningsökning på 36 procent i Q3, drivet av bredare efterfrå...
Alzecure drar i gång en avslutande fas 1-studie med ACD-856 för att dokumentera högre doser jämfört ...
Redeye gives a short comment on the news that the FDA has accepted Ascelia’s NDA application for Orv...
Redeye updates its estimates and valuation following Navigo releasing its Q3 2025 report.
Smart Eye’s Q3 report tracked closely with our expectations, with Automotive once again acting as th...
* Q3e: -22% y-o-y top-line decline * ABGSCe in line with low end of '25e guidance * Trading ~10% bel...
Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv3 2025-rapport över förväntan både vad ...
